Active	Status	Sponsor type	Region	Phase	Filter
6 Active 6 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schuster, Stephen J
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas	Terminated	2	55	US	DTRM-555, DTRMWXHS-12, everolimus, pomalidomide	Zhejiang DTRM Biopharma	Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation	12/24	12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies	Recruiting	2	42	US	mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101	Abramson Cancer Center at Penn Medicine, Genentech, Inc.	Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma	12/24	12/25
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL Presentation of P1 data from P1/2 trial for CLL at ASH 2018 Dec 2018 - Dec 2018: Presentation of P1 data from P1/2 trial for CLL at ASH 2018 From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] Dec 2018 - Dec 2018: From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] More	Recruiting	1/2	320	Canada, US	JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax	Juno Therapeutics, a Subsidiary of Celgene	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	11/27	11/27
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
Jewusiak, Jessica
No trials found